BioSpace News Archive

Portal Biotechnologies, Inc., a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.

Biogen Canada Inc. announced that Health Canada has accepted for review a New Drug Submission for tofersen for the treatment of amyotrophic lateral sclerosis in adults who have a mutation in the superoxide dismutase 1 gene.

Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® in the United Kingdom.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces a proposed capital return of $100 million to its shareholders by way of a tender offer.

Vicore Pharma Holding AB announced FDA Breakthrough Device Designation status for AlmeeTM, a 9-week digital cognitive behavioral therapy, to be used as an adjunct treatment of anxiety symptoms related to PF.

Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced its participation in the following upcoming conferences.

Telum Therapeutics is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer.

Solventum will host its inaugural Investor Day in New York City ahead of its planned spinoff from 3M.

Boehringer Ingelheim announced that the US FDA has approved SPEVIGO® injection for the treatment of generalized pustular psoriasis in adults and pediatric patients aged 12 and above weighing ≥40 kg.5 This approval follows the Chinese National Medical Products Administration’s recent approval of SPEVIGO® for the reduction of occurrence of generalized pustular psoriasis in adolescents from 12 years of age with a body weight ≥40 kg and adults.

Century Therapeutics announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.